Medications That Cause Neuropathy: 7 Real Updates From 2026 (and What Is Still Fear)

Many people first wonder whether a medicine is hurting their nerves after reading a leaflet, a forum thread or a frightening headline. Numbness, tingling and burning in the feet can have more than 200 causes, and a medicine is one of them for some people, but only some medicines, and often only under certain conditions.

This page lists seven updates from 2026 on medicines and nerve damage, in order of how useful each is to you. For every item we give the date, where it was published, who was studied, and what to do. One rule comes before all of them: never stop or change a prescribed medicine on your own. The risk of an untreated infection, diabetes, heart rhythm problem or cancer is usually larger than the risk to your nerves. It is a companion to our complete guide to peripheral neuropathy.

1. A January 2026 JAMA Review Lists the Medicines Behind Toxic Neuropathy and the First Tests to Ask For

Status: practical now. Published January 20, 2026 in JAMA. An expert review of the evidence.

This review of peripheral neuropathy says it affects about 1% of adults worldwide and has more than 200 causes. Diabetes is the most common, accounting for more than half of cases in Western populations. Among toxic causes it names chemotherapy drugs (cisplatin, paclitaxel, vincristine), the heart-rhythm drug amiodarone and older HIV drugs called nucleoside reverse transcriptase inhibitors (stavudine, zalcitabine). It also lists alcohol and vitamin B12 deficiency. Up to 27% of adults with neuropathy still have no identifiable cause after testing.

The recommended first tests are blood glucose (for diabetes), serum B12 with its metabolites (methylmalonic acid, with or without homocysteine) and a blood test for abnormal proteins called serum protein electrophoresis with immunofixation. The review also warns that complete reversal of nerve damage is uncommon even when a cause can be treated.

What it means for you: the second sentence matters most. Because recovery can be partial, catching a drug effect early is worth more than any treatment afterward. Bring a list of every prescription, over-the-counter medicine and supplement to your appointment, and say when the symptoms began relative to each one. Cancer treatment is covered in our chemo neuropathy news for 2026.

2. A Huge UK Study Found No Extra Nerve Risk From Fluoroquinolone Antibiotics

Status: reassuring, with limits. Published in Neurology (issue of November 24, 2026, online ahead of print). Tested in people through health records.

Fluoroquinolones (ciprofloxacin and levofloxacin are common examples) carry warnings about nerve damage that may be lasting, based mostly on case reports. This study used two UK primary-care databases covering 1997 to 2019. It compared adults without diabetes or earlier neuropathy who were prescribed a fluoroquinolone with adults prescribed cephalosporins, another antibiotic family: 2,933,982 people in one database and 995,457 in the other. It then looked for new peripheral neuropathy within 60 days.

The result was close to no difference: a pooled hazard ratio of 0.96 (95% CI 0.77 to 1.20) at the first treatment and 1.05 (0.92 to 1.20) across all treatments. As a check, the authors also measured tendon rupture, a risk known to be higher with these drugs, and found it elevated (1.98), which shows the method can detect a real effect. They conclude the findings “provide some reassurance” and note that residual confounding is a limit.

People with diabetes were excluded, so the study cannot speak for them, and it looked only at neuropathy in the first 60 days.

What it means for you: it does not erase the warnings, and the authors of the reporting analyses below advise caution for mild infections. If you were prescribed one for a good reason, this study is a reason not to panic. If you develop numbness, burning or weakness while taking one, call your doctor the same day.

3. Adverse-Event Reports Still Flag a Fluoroquinolone Signal

Status: a warning signal, not a measured risk. Published August 31, 2026 in the International Journal of Antimicrobial Agents and April 2026 in Clinical and Translational Science. Analyses of reports submitted to regulators.

The August analysis examined 6,451 fluoroquinolone-related neuropathy reports in the U.S. FDA Adverse Event Reporting System from 2004 to 2025 and checked the signal against a Canadian database. Every fluoroquinolone showed a signal. Ciprofloxacin (odds ratio 2.71) and levofloxacin (1.88) were reported more often than moxifloxacin. Onset was fast, with a median of 4 to 5 days, and longer treatment and use of the antibiotic nitrofurantoin at the same time were linked to higher reporting odds.

The April analysis found similar signals, including for the newer gemifloxacin. It noted that women and adults aged 18 to 64 were more common in the reports, while men and people 65 and older were more common among fatal outcomes, and that regulators have recognized the risk of persistent and potentially irreversible nerve effects.

Reports show that a problem was submitted, not how often it happens. People can report for many reasons and there is no comparison group, which is why a cohort like the one above matters. Both papers call for careful weighing of benefit and risk, especially for long courses of oral treatment.

What it means for you: the two kinds of evidence point in slightly different directions, so the honest summary is “uncommon, but real enough to take seriously.” Ask whether a different antibiotic would work, and treat any new nerve symptom during a course as a reason to call.

4. Metformin Users Rarely Get the Vitamin B12 Tests That Guidelines Recommend

Status: practical now; ask your doctor. Published April 20, 2026 in BMJ Open. A scoping review of 23 sources.

Long-term metformin use is linked to vitamin B12 deficiency, which can lead to anemia and neuropathy, and international bodies recommend screening for it. This review asked whether that happens. Across 15 studies of screening practice, annual B12 testing was uncommon, generally below 20% of eligible patients (range 2.6% to 19.8%). In one large cohort of long-term users, 44.9% were ever tested, on average 990 days after starting. Testing was mostly triggered by symptoms rather than done in advance, and older adults and other high-risk groups were less likely to be tested. No studies from the UK were found.

What it means for you: if you have taken metformin for years, ask whether a B12 check is due, especially if you have numbness or tingling, are over 60 or eat little animal food. Correcting a true deficiency is one of the few fixable causes of neuropathy. Our guide to vitamin B12 and nerve pain explains who is at risk.

5. Stopping Metformin Was Linked to More Neuropathy, Not Less

Status: do not stop metformin over B12 fears. Published October 2026 in Metabolic Syndrome and Related Disorders. Tested in people through health records.

If metformin lowers B12, could it cause neuropathy? A matched cohort study looked at people with type 2 diabetes who were prescribed a second glucose-lowering medicine. It compared those who kept taking metformin with those who did not, with 58,027 people in each group after matching. People who stopped had a higher risk of polyneuropathy (adjusted hazard ratio 1.26, 95% CI 1.23 to 1.29), plus more foot ulcers and amputations. A separate Taiwanese cohort of 31,384 matched pairs gave a similar result (1.25). The authors suggest B-vitamin supplementation may add to the benefit.

This is an association. People who stop a medicine may differ in other ways, such as how well their diabetes is controlled, so it cannot prove metformin protects nerves. It does suggest that B12 depletion is not a reason to drop a drug that helps blood sugar, which is a major driver of diabetic nerve damage. See our guide to how diabetes damages nerves.

What it means for you: keep taking metformin as prescribed, and handle B12 as a separate question with a blood test.

6. Adjusting Linezolid for Nerve Symptoms Did Not Hurt Tuberculosis Cure Rates

Status: doctor-led decisions only. Published June 12, 2026 in Clinical Infectious Diseases. Tested in people through observational data.

Linezolid is an antibiotic used for drug-resistant tuberculosis, and a known side effect is peripheral neuropathy that can force doses to be cut or paused. Researchers emulated a randomized trial using data from 303 people in 12 countries who developed non-severe neuropathy on linezolid. Treatment success was 84.7% when the dose was changed right away, 85.2% when it was left unchanged and 78.9% when changes were delayed. The authors found no evidence of a substantial negative effect of changing the dose promptly and say the results support cautious adjustment.

Because it is observational and covers only non-severe cases, it cannot replace a doctor’s judgment about your treatment.

What it means for you: if you take linezolid and notice nerve symptoms, report them early. Waiting did not look better than acting, and your doctor can weigh a dose change against your cure.

7. Immunotherapy Can Cause a Mostly Demyelinating Neuropathy, and Early Testing Helps

Status: report symptoms early. Published October 12, 2026 in the Journal of Clinical Neurophysiology. A small case series and literature review.

Immune checkpoint inhibitors are cancer drugs that release the immune system, and in some patients it also attacks nerves. The authors analyzed 50 patients, 8 from their center and 42 from published reports. In most the pattern was demyelinating, meaning damage to the insulating coat of nerves, affecting both arms and legs. Limb weakness was the first symptom in 6 of the 8 center patients and in 41 of the 42 reported cases, with tingling first in 2 of 8 and 39 of 42. They conclude that prompt electromyography, a nerve conduction test, after symptoms begin can help detect nerve involvement and allow earlier treatment.

This is a small group, so it describes what the problem looks like rather than how common it is.

What it means for you: if you are on immunotherapy, new weakness or tingling in your arms or legs is worth reporting at once, not at your next scheduled visit.

What Should You Do If You Suspect a Medicine Is Affecting Your Nerves?

1. Do not stop it by yourself. Call your doctor or pharmacist the same day for new numbness, burning or weakness, especially in the first days of a new medicine.
2. Write down the timeline. When did you start each medicine or change a dose, and when did the symptoms begin?
3. Bring everything. Include over-the-counter medicines, vitamins and supplements, because too much vitamin B6 can itself harm nerves (see our guide to foods and nutrients for nerve health).
4. Ask for the first tests. Blood sugar, B12 and a protein test are the starting point in the JAMA review.
5. Ask about alternatives. Sometimes a different drug, a lower dose or a shorter course is possible.

You can also look up any treatment in testing on ClinicalTrials.gov, the free U.S. government registry.

Frequently Asked Questions